Navigation Links
BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of its 2012 Annual Report
Date:3/18/2013

xone.  In September 2012, BDSI announced a positive outcome of the pivotal pharmacokinetic study and in January 2013 announced completion of the safety study, which demonstrated favorable tolerability in 249 opioid dependent subjects switched from Suboxone to BUNAVAIL.  
  • ONSOLIS/BREAKYL.  In October, BDSI announced the commercial launch of BREAKYL (fentanyl buccal film) in the European Union.  Under the terms of its agreement with its commercial partner Meda, BDSI received a final milestone payment of $2.5 million and will also receive a royalty on net sales of BREAKYL in the E.U.  The launch of BREAKYL also triggered the recognition of $17.5 million of previously deferred revenue.
  • $40 Million Registered Financing.  In December, BDSI closed a registered direct financing (priced at market and with no warrant coverage) which yielded gross proceeds of $40 million to BDSI, of which 70% was received from current investors.  Proceeds are expected to fund the clinical programs of both BEMA Buprenorphine and BUNAVAIL while providing a strong balance sheet for potential licensing discussions for BUNAVAIL for both the U.S. and abroad or as BDSI considers commercializing BUNAVAIL on its own.
  • Anticipated 2013 Milestones

    BDSI is focusing its resources on achievement of the following key milestones:

    • Submission of BUNAVAIL NDA for opioid dependence.  Based on demonstrating bioequivalence in the pivotal pharmacokinetic study and positive results in the safety study, BDSI anticipates it will submit a New Drug Application (NDA) to the FDA for BUNAVAIL in mid-2013.
    • Recruitment of two Phase 3 studies for BEMA Buprenorphine.  BDSI and Endo expect to continue recruitment in the two Phase 3 efficacy studies for BEMA Buprenorphine for chronic pain, one in opioid experienced and one in opioid naïve patient
      '/>"/>

    SOURCE BioDelivery Sciences International, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. BioDelivery Sciences Announces Positive Results from BEMA Buprenorphine/Naloxone (BNX) Pharmacokinetic Study
    2. BioDelivery Sciences and Endo Health Solutions Announce Initiation of Enrollment in the Phase 3 Program for BEMA Buprenorphine for Chronic Pain
    3. BioDelivery Sciences to Present at the 2012 Wedbush PacGrow Lifesciences Management Access Conference
    4. BioDelivery Sciences Announces Completion of Enrollment in Pivotal Pharmacokinetic Study of BEMA Buprenorphine/Naloxone Compared to Suboxone
    5. BioDelivery Sciences to Present at the Stifel Nicolaus 2012 Healthcare Conference
    6. BioDelivery Sciences Announces Positive Results of Pivotal Pharmacokinetic Study Comparing BEMA Buprenorphine/Naloxone (BNX) to Suboxone
    7. BioDelivery Sciences Provides Business Update and Summary of Third Quarter Results of Operations
    8. BioDelivery Sciences to Present at the 24th Annual Piper Jaffray Healthcare Conference
    9. BioDelivery Sciences Announces $40 Million Registered Financing
    10. BioDelivery Sciences Announces Completion of BNX Safety Study
    11. BioDelivery Sciences to Present at the 15th Annual BIO CEO and Investor Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/23/2014)... HARRISBURG, Pa. , Sept. 23, 2014 ... prescription drugs Sat., Sept. 27, as part of National ... anonymous, no questions asked. Take-Back Day is ... Drug Enforcement Administration (DEA), aimed at encouraging the public ... that are prone to abuse and theft. ...
    (Date:9/23/2014)... 2014 Galmed Pharmaceuticals Ltd. (Nasdaq: ... focused on the development and commercialization of a ... diseases and cholesterol gallstones, announced today that the ... approved its request for Fast Track Designation of ... Non-Alcoholic Steato-Hepatitis, or NASH.  FDA ...
    (Date:9/23/2014)... , Sept 23, 2014  Vesselon, Inc. today announced ... of Directors, effective September 15, 2014. Dr. Raths, appointment ... its placement agent to market a private preferred Series ... early stroke treatment. "Jurgen,s deep experience across ... a great asset to Vesselon as we develop our ...
    Breaking Medicine Technology:Galmed Pharmaceuticals Announces U.S. FDA Approval of Fast Track Designation of Aramchol for the Treatment of NASH 2Galmed Pharmaceuticals Announces U.S. FDA Approval of Fast Track Designation of Aramchol for the Treatment of NASH 3Vesselon Announces Jurgen Raths, MD to Serve on Board of Directors 2Vesselon Announces Jurgen Raths, MD to Serve on Board of Directors 3
    ... Novavax, Inc. (Nasdaq:,NVAX) today announced that it ... vaccine candidate against Severe Acute Respiratory Syndrome,(SARS). The ... Institutes of Health (NIH) to continue preclinical development ... "Until now, it has been difficult to ...
    ... Three of Four HUMIRA Patients from CHARM Study in Remission ... ... May 21 Results from an,open-label extension study of two ... patients treated with,HUMIRA(R) (adalimumab) achieved long-term clinical remission and clinical,response, ...
    Cached Medicine Technology:Novavax Announces Proprietary Method to Create SARS Vaccine and Renewal of NIH Funding for SARS Vaccine Development 2Novavax Announces Proprietary Method to Create SARS Vaccine and Renewal of NIH Funding for SARS Vaccine Development 3Abbott Presents Long-Term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission 2Abbott Presents Long-Term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission 3Abbott Presents Long-Term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission 4Abbott Presents Long-Term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission 5Abbott Presents Long-Term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission 6Abbott Presents Long-Term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission 7
    (Date:9/23/2014)... CA (PRWEB) September 23, 2014 Oaksterdam ... Industry Today . In its first post, the University ... growing and changing cannabis industry. , The cannabis industry ... Colorado alone is expecting an 18-month boost of more ... and adult use pot sales. And, the new legal ...
    (Date:9/23/2014)... throughout the first year follow a set of ... syllables and first words. However, previous research had ... differ between hearing and deaf infants. Now, University ... primarily motivated by infants, ability to hear their ... who received cochlear implants to help correct their ...
    (Date:9/23/2014)... FL (PRWEB) September 23, 2014 ... of the newly renovated Women’s Health Center on ... feet of space, the specially designed center offers ... in East Pasco County. The Women’s Health Center ... pelvic floor health, labor and delivery through The ...
    (Date:9/23/2014)... "The primary purpose of the CALL LIGHT CADDY is ... Ca.. "Call lights are often found on the floor, lost ... pole out of the patient's reach. In order to make ... need it, I created this caddy." , She developed the ... within easy reach. The accessory ensures that the call device ...
    (Date:9/23/2014)... studies found that FDG-PET technology is less accurate ... regions where infections like histoplasmosis or tuberculosis are ... cancer could lead to unnecessary tests and surgeries ... , Histoplasmosis and other fungal diseases are ... bird droppings and are found in soils. , ...
    Breaking Medicine News(10 mins):Health News:Oaksterdam University Addresses "Why Quality Training Matters in a Growing Marijuana Industry" in First Blog Post 2Health News:Oaksterdam University Addresses "Why Quality Training Matters in a Growing Marijuana Industry" in First Blog Post 3Health News:Infant cooing, babbling linked to hearing ability, MU researcher finds 2Health News:Florida Hospital Zephyrhills Celebrates Grand Opening of Women’s Health Center 2Health News:Florida Hospital Zephyrhills Celebrates Grand Opening of Women’s Health Center 3Health News:Study questions accuracy of lung cancer screens in some geographic regions 2
    ... the time in emergency rooms , , TUESDAY, Dec. 18 (HealthDay ... someone is having a heart attack, they are mistaken 9.2 ... that minutes matter with these patients and doctors have to ... say researchers from the Minneapolis Heart Institute Foundation. , "Our ...
    ... three and older in the United States would carry ... the 2008 University of Louisville Grawemeyer Award in Education. ... nations young children, fill a gap for working families, ... boost the economy, award winners Edward Zigler, Walter Gilliam ...
    ... led by Mayo Clinic have designed a technique that uses ... cells that spread from primary tumors to other parts of ... shows that this technology could be the basis for a ... appeared in the Dec. 9 online issue of Nature Medicine. ...
    ... inexpensive infection control measures, hospitals around the world could prevent ... TB), according to a new study in The Lancet by ... Wings for its ability to spread and kill rapidly, XDR ... identified in all regions of the world, including the United ...
    ... for patients with spinal cord injuries can stimulate ... compensatory changes in the brain, say Canadian researchers. ... function and the ability to walk. , A ... the remarkable benefits of rehabilitation training after a ...
    ... remains America,s No. 1 killer, AHA says , , TUESDAY, ... death rates in the United States are declining, the ... the nation, according to the American Heart Association. , ... for many people, according to the American Heart Association,s ...
    Cached Medicine News:Health News:Diagnosis of Heart Attack Can Be Wrong 2Health News:Researchers train the immune system to deliver virus that destroys cancer in lab models 2Health News:Researchers train the immune system to deliver virus that destroys cancer in lab models 3Health News:Simple strategy could prevent half of deadly tuberculosis infections 2Health News:Intensive training post-spinal cord injury can stimulate repair in brain and spinal cord 2Health News:U.S. Heart Disease Death Rates Falling 2Health News:U.S. Heart Disease Death Rates Falling 3
    ... cage system provides anterior column support for ... from T1 to L5. The system consists ... polymer cages that are stacked to a ... Peek Carbon fiber reinforced polymer material emulates ...
    ... is an extrudable, moldable bone void filler that ... anywhere in the skeletal system, including extremities, the ... as a temporary scaffolding for new bone formation. ... X-ray, making healing easier to assess. Boneplast kit ...
    ... CE mark for its synthetic bone substitute Ossatura. ... of a smart material, i.e. a material that ... of events in the musculo-skeletal system that results ... and improved fusion, and reduces in part or ...
    ... Cerasorb bone regeneration ... beta-tricalcium phosphate composite ensures ... unique spherical structure maximizes ... Permeability is the most ...
    Medicine Products: